Centaur Pharmaceuticals is a fully integrated Indian pharmaceutical player with proficiencies across API, Formulations, Clinical Research and Contract Manufacturing. Centaur has strategic alliances with global majors and innovators and is devoted to quality. The Centaur foot-print encompasses 120 countries. Centaur is India’s 34th largest pharmaceutical firm by prescriptions with a strong presence in Asia, South America and Africa. Centaur has a pan India reach, with leadership across 6 therapy segments. Centaur manufactures Sinarest, India’s No.1 anti-cold, since 1996, exclusively at its state of the art USFDA approved Goa facility. Sinarest is the only brand in India to have won the ‘Brand of the Year for Marketing Excellence’, seven times in a row. Centaur has two WHO-GMP approved formulations facilities in Goa for India and ROW markets. Centaur’s fully scalable 25,000 sqm finished dosage formulations facility, caters to international markets. The annual capacity of the facility is 3 billion tablets and 600 million capsules. The facility houses the formulations R&D and analytical development sections.

Clinical Research : LifeSan, the clinical research arm of Centaur conducts clinical trials, and BA-BE studies. The facility has been successfully inspected by USFDA and approved by CDSCO India.

Innovation : Centaur introduced Woxheal, a new chemical entity (NCE), with German collaboration, for the first time in the world, in India. Centaur conducted phase II and III clinical trials in India for Woxheal and then developed the API and formulations in house. Woxheal treats diabetic foot ulcer, which is an unmet need, and helps save precious limbs from amputation.